BOSTON--(BUSINESS WIRE)--Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB), a biopharmaceutical company, today announced that it has acquired Quellis Biosciences Inc. (“Quellis”), a privately-held ...

The approval by the FDA last year for Sarepta’s DMD drug Exondys 51 (eteplirsen) buoyed many in this research space, but last night we were all reminded of how tough this disease area can be after ...

Once-struggling, Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is looking to hit the reset button with a new name and focus. Catabasis has been dragging for several years, weighed down mainly by the ...

As every investor would know, not every swing hits the sweet spot. But you want to avoid the really big losses like the plague. So take a moment to sympathize with the long term shareholders of ...

Catabasis Pharmaceuticals Inc.’s stock plunged in after-hours trading Tuesday after the Cambridge biotech said its treatment for Duchenne muscular dystrophy did not meet goals for patient improvement ...

Catabasis has conceded defeat with its Duchenne muscular dystrophy drug edasalonexent, pulling the plug on the drug after a phase 3 trial echoed the results of a failed mid-stage study. The PolarisDMD ...

Catabasis Pharmaceuticals, a biopharmaceutical company, has inked about $110 million in a private placement. Perceptive Advisors is the lead investor. Other investors include Fairmount Funds ...

CAMBRIDGE, Mass.--(EON: Enhanced Online News)--Catabasis Pharmaceuticals, a biopharmaceutical company developing novel therapeutics for the treatment of inflammatory and metabolic diseases, today ...

Multiple biological pathways go awry to cause disease. Cambridge startup Catabasis is developing a platform to simultaneously modulate multiple targets in a disease pathway, with a focus on diseases ...

-- Recently Completed Acquisition of Quellis Biosciences Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of ...

Acquisition Includes QLS-215, a Potential Best-in-Class Monoclonal Antibody Inhibitor of Plasma Kallikrein in Preclinical Development for the Treatment of Hereditary Angioedema Company Plans to Use ...